Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 31;10(6):397.
doi: 10.3390/jof10060397.

In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China

Simin Yang  1 , Feifei Wan  1 , Min Zhang  1 , Huiping Lin  1 , Liang Hu  1 , Ziyi Zhou  1 , Dongjiang Wang  1 , Aiping Zhou  1 , Lijun Ni  1 , Jian Guo  1 , Wenjuan Wu  1
Affiliations

In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China

Simin Yang et al. J Fungi (Basel). .

Abstract

The efficacy of different echinocandins is assessed by evaluating the in vitro activity of a novel antifungal, rezafungin, against invasive fungal isolates in comparison with anidulafungin and caspofungin. Using the broth microdilution (BMD) method, the susceptibility of 1000 clinical Candida isolates (including 400 C. albicans, 200 C. glabrata, 200 C. parapsilosis, 150 C. tropicalis and 50 C. krusei) and 150 Aspergillus isolates (100 A. fumigatus and 50 A. flavus) from the Eastern China Invasive Fungi Infection Group (ECIFIG) was tested for the antifungals including anidulafungin, rezafungin, caspofungin and fluconazole. The echinocandins showed strong activity against C. albicans that was maintained against fluconazole-resistant isolates. The GM MIC (geometric mean minimum inhibitory concentration) value of rezafungin was found to be comparable to that of anidulafungin or caspofungin against the five tested common Candida species. C. tropicalis exhibited higher resistance rates (about 8.67-40.67% in different antifungals) than the other four Candida species. Through the sequencing of FKS genes, we searched for mutations in echinocandin-resistant C. tropicalis isolates and found that all displayed alterations in FKS1 S654P. The determined MEC (minimal effective concentration) values against A. fumigatus and A. flavus for rezafungin (0.116 μg/mL, 0.110 μg/mL) are comparable to those of caspofungin (0.122 μg/mL, 0.142 μg/mL) but higher than for anidulafungin (0.064 μg/mL, 0.059 μg/mL). Thus, the in vitro activity of rezafungin appears comparable to anidulafungin and caspofungin against most common Candida and Aspergillus species. Rezafungin showed higher susceptibility rates against C. glabrata. Rezafungin indicates its potent activity for potential clinical application.

Keywords: anidulafungin; caspofungin; echinocandins; invasive fungal infection; rezafungin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The source distribution of the five Candida species.
Figure 2
Figure 2
MICs of anidulafungin, rezafungin and caspofungin for C. albicans isolates. ANI, anidulafungin; REZA, rezafungin; CAS, caspofungin.
Figure 3
Figure 3
MICs of anidulafungin, rezafungin and caspofungin against four common non-albicans Candida isolates. (A): MICs against C. glabrata; (B): MICs against C. parapsilosis; (C): MICs against C. tropicalis; (D): MICs against C. krusei. ANI, anidulafungin; REZA, rezafungin; CAS, caspofungin.
Figure 4
Figure 4
MECs of anidulafungin, rezafungin and caspofungin against two common Aspergillus isolates. ANI, anidulafungin; REZA, rezafungin; CAS, caspofungin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gonzalez-Lara M.F., Ostrosky-Zeichner L. Invasive Candidiasis. Semin. Respir. Crit. Care Med. 2020;41:3–12. doi: 10.1055/s-0040-1701215. - DOI - PubMed
    1. Du H., Bing J., Hu T., Ennis C.L., Nobile C.J., Huang G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020;16:e1008921. doi: 10.1371/journal.ppat.1008921. - DOI - PMC - PubMed
    1. Pappas P.G., Lionakis M.S., Arendrup M.C., Ostrosky-Zeichner L., Kullberg B.J. Invasive candidiasis. Nat. Rev. Dis. Primers. 2018;4:18026. doi: 10.1038/nrdp.2018.26. - DOI - PubMed
    1. Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Ostrosky-Zeichner L., Reboli A.C., Schuster M.G., Vazquez J.A., Walsh T.J., et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2016;62:e1–e50. doi: 10.1093/cid/civ933. - DOI - PMC - PubMed
    1. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ellis D.J., Tullio V., Rodloff A.C., Fu W., Ling T.A., Global Antifungal Surveillance Group Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 2010;48:1366–1377. doi: 10.1128/JCM.02117-09. - DOI - PMC - PubMed

LinkOut - more resources